Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 4)

Link copied
Case Copied 36 min read

FEDERAL COURT OF AUSTRALIA

Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 4) [2011] FCA 1307

Citation: Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 4) [2011] FCA 1307
Parties: SANOFI-AVENTIS AUSTRALIA PTY LTD ACN 008 558 807, SANOFI-AVENTIS DEUTSCHLAND GMBH and AVENTISUB II INCORPORATED v APOTEX PTY LTD ACN 096 916 148
File number(s): NSD 1664 of 2008
Judge: JAGOT J
Date of judgment: 18 November 2011
Catchwords:

COPYRIGHT – construction and effect of amendments introduced by Therapeutic Goods Legislation Amendment (Copyright) Act 2011 (Cth)

CONSUMER LAW – misleading and deceptive conduct – form of declaration relating to threatened misleading and deceptive conduct

DAMAGES – release from undertaking as to damages

PATENTS – form of declaration and injunction regarding threatened patent infringement

PRACTICE AND PROCEDURE – where parties at trial had assumed particular construction of legislation which had yet to commence – whether applicants required leave to re-open case in order to contend for a different construction

STATUTORY INTERPRETATION – Copyright Act 1968 (Cth) s 44BA – meaning of “a work that is product information approved under section 25AA of the Therapeutic Goods Act 1989 in relation to medicine”

Legislation: Acts Interpretation Act 1901 (Cth) ss 15, 15AA, 15AB
Copyright Act 1968 (Cth) ss 10, 44B, 44BA, 47AB, 47B
Therapeutic Goods Act 1989 (Cth) ss 3, 7D, 23, 25, 25A, 25AA
Therapeutic Goods Legislation Amendment (Copyright) Act 2011 (Cth) Sch 1 s 2
Cases cited: Autodesk Inc v Dyason (No 2) (1993) 176 CLR 300
Commonwealth v Verwayen (1990) 170 CLR 394
IceTV Pty Ltd v Nine Network Australia Pty Ltd (2009) 239 CLR 458
Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd(No 3) (2011) 92 IPR 320; [2011] FCA 846
University of Wollongong v Metwally (No 2) (1985) 60 ALR 68
Date of hearing: 30 September and 10 November 2011
Place: Sydney
Division: GENERAL DIVISION
Category: Catchwords
Number of paragraphs: 54
Counsel for the Applicants: Mr R Cobden SC with Mr C Dimitriadis and Mr A R Lang
Solicitor for the Applicants: Jones Day
Counsel for the Respondent: Mr D K Catterns QC with Mr N R Murray
Solicitor for the Respondent: Freehills

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 1664 of 2008  

BETWEEN:

SANOFI-AVENTIS AUSTRALIA PTY LTD ACN 008 558 807
First Applicant

SANOFI-AVENTIS DEUTSCHLAND GMBH
Second Applicant

AVENTISUB II INCORPORATED
Third Applicant

AND: APOTEX PTY LTD ACN 096 916 148
Respondent

JUDGE:

JAGOT J

DATE OF ORDER:

18 NOVEMBER 2011

WHERE MADE:

SYDNEY

THE COURT DECLARES THAT:

1.The Respondent/Cross-Claimant has infringed the copyright in version B and version 19 of the Arava product information (together, the Arava Pl) and the Arava Summary of Product Characteristics (Arava SPC) by, prior to 28 May 2011, reproducing in a material form a substantial part of each of those works in the form of the product information for the Respondent/Cross-Claimant’s leflunomide-containing products approved by the Therapeutic Goods Administration in July 2008 (the approved Apotex Pl

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 4) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2011] FCA 1307
Decision Date

CaseChat Overview and Summary

In the case of Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 4), the High Court addressed several critical issues surrounding the interpretation and application of the Therapeutic Goods Legislation Amendment (Copyright) Act 2011 (Cth). This case involved a dispute between Sanofi-Aventis and Apotex over patent infringement, misleading and deceptive conduct, and copyright infringement. The court was required to decide whether Sanofi-Aventis was entitled to relief for copyright infringement after the commencement of the amendment Act, the necessity of additional declarations regarding threatened infringements and misleading conduct, and the release of an undertaking as to damages.

The court first examined the impact of the amendment Act on the copyright infringement claim. The amendment Act, which came into effect after the hearing but before the principal judgment, was assumed by both parties to negate any breach of copyright in respect of the works on which Sanofi-Aventis relied. However, Sanofi-Aventis later contended that the amendment Act operated differently than previously assumed, particularly concerning the SPC. The court held that the SPC, in part, constituted product information as approved, and thus, the provisions of the amendment Act exempted the proposed future acts from copyright infringement. Consequently, Sanofi-Aventis was not entitled to any relief for copyright infringement post the commencement of the amendment Act.

The court also addressed the necessity of additional declarations regarding threatened infringements and misleading conduct. Sanofi-Aventis sought declarations to reflect the findings of the principal judgment, while Apotex argued that such declarations were unnecessary. The court found that the declarations were necessary to clarify the legal position and should be consistent with the terms of the patent injunction.

Finally, the court considered the release of the undertaking as to damages. Apotex opposed the release on the basis that Sanofi-Aventis did not disavow the potential argument that the release of the undertaking might deprive Apotex of its benefit should it succeed in its anticipated appeal. The court decided that for abundant caution, the release of the undertaking should be qualified to specify its effective date and avoid any confusion regarding its implications.

The court's reasoning led to specific orders, including the denial of relief for copyright infringement post the amendment Act, the qualification of the release of the undertaking as to damages, and the necessity of additional declarations to reflect the court's findings. These decisions provided clarity and finality to the legal issues raised in the case, ensuring that the parties understood the implications of the court's rulings.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

These reasons for judgment deal with the orders which should be made as a consequence of the publication of the principal judgment in this matter on 29 July 2011 (Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd(No 3) (2011) 92 IPR 320; [2011] FCA 846, referred to below as the principal judgment). Terms defined in the principal judgment have the same meaning in these reasons. In the principal judgment I found as follows:(1)“Apotex has not established that the claim of the patent is invalid. Sanofi-Aventis has established that Apotex’s proposed supply of Apotex’s leflunomide product for the treatment of PsA will infringe the patent. Sanofi-Aventis is thus entitled to declarations and an injunction generally in accordance with paras 14 to 16 of the amended application” (at [274]).(2)In respect of the misleading and deceptive conduct claims, “Sanofi-Aventis has established a proper basis for the making of declarations and injunctions to the general effect of those in paras 19-21 of the amended application (albeit not by reference to all of the representations on which it relied)” (at [282]).(3)“Sanofi-Aventis has established that Apotex, without a licence to do so, infringed copyright in the Arava works on which Sanofi-Aventis relied (the SPC, the Arava PI version B and the Arava PI version 19) in contravention of s 36 of the [Copyright Act 1968 (Cth)]. The [Therapeutic Goods Legislation Amendment (Copyright) Act 2011 (Cth)], however, must be taken into account. The parties may wish to be heard on that issue” (at [384]). The orders which should be made as a result of these findings are, in part, in dispute. The issue of costs is also outstanding, although the parties agree that consideration of the appropriate costs orders should be deferred pending the making of the substantive orders. In these reasons, I deal with the disputed issues by reference to a document which the parties prepared identifying the orders each contends should be made. THE COPYRIGHT ISSUELeave to re-open? The copyright issue involves the operation of the Therapeutic Goods Legislation Amendment (Copyright) Act 2011 (Cth), referred to in the principal judgment as the amendment Act. The amendment Act commenced on 28 May 2011, after the hearing but before the publication of the principal judgment. The principal judgment at [283]-[285] discloses that, both during the hearing and when I made consent orders on 31 May 2011 setting aside the interlocutory injunction of 30 November 2008, the parties shared an assumption that the amendment Act, once commenced, would negate any breach of copyright in respect of any of the copyright works on which Sanofi-Aventis relied (that is, the works known as the SPC, the Arava PI version B and the Arava PI version 19). Sanofi-Aventis now contends that the amendment Act operates in respect of the Arava PI version B and the Arava PI version 19 but not the SPC, with the consequence that it is entitled to orders restraining any further breaches of its copyright in the SPC. Apotex contends that Sanofi-Aventis requires leave to re-open its case in respect of this issue and that, if leave is granted over Apotex’s objection, Sanofi-Aventis should be found to have misconstrued the amendment Act or should be denied any relief in the exercise of discretion.

Ratio Decidendi

Legal Principle Established

The SPC, in part, is product information as approved. The part of the SPC that is product information as approved is the part which enabled Sanofi-Aventis to contend that in reproducing the Arava PI version 21 (the most recently approved PI for Arava) Apotex also indirectly reproduced a substantial part of the SPC and thus infringed Sanofi-Aventis’s copyright in the SPC (as found at [360] of the principal judgment). The fact that the SPC, in part, is product information as approved – and that I am satisfied that this part is itself a work in which copyright subsists – is sufficient to engage ss 44BA(1) and (2) of the Copyright Act. The acts proposed to be carried out in the future by Sanofi-Aventis are within the scope of the exemption created by those provisions. It follows that Sanofi-Aventis is not entitled to any relief in respect of infringement of copyright after the commencement of the amendment Act on 28 May 2011. ADDITIONAL DECLARATIONS Sanofi-Aventis claims that declarations should be made in respect of Apotex’s threatened infringements of the patent and threatened misleading and deceptive conduct. Apotex opposes the making of those declarations on the basis that, by reason of the substantive orders, they are unnecessary. As Sanofi-Aventis submitted, the declarations reflect the findings at [274] and [282] of the principal judgment as follows:[274]Apotex has not established that the claim of the patent is invalid. Sanofi-Aventis has established that Apotex’s proposed supply of Apotex’s leflunomide product for the treatment of PsA will infringe the patent. Sanofi-Aventis is thus entitled to declarations and an injunction generally in accordance with paras 14 to 16 of the amended application.[…][282]For these reasons Sanofi-Aventis has established a proper basis for the making of declarations and injunctions to the general effect of those in paras 19-21 of the amended application (albeit not by reference to all of the representations on which it relied). The terms of the declarations are also in dispute. In respect of the declarations relating to threatened infringement of the patent, the same issues arise as in relation to the injunction. I deal with this aspect of the dispute below in the context of the injunction and on the basis that the declaration and injunction, insofar as possible, should be consistent. In respect of the declaration relating to the threatened misleading and deceptive conduct, I agree with Apotex’s position that it is unnecessary to record the specific representations which I found would be made by the threatened conduct and would be misleading and deceptive if made. Otherwise, the identification of the relevant conduct in this declaration also should be consistent with the terms of the patent injunction. RELEASE OF THE UNDERTAKING AS TO DAMAGES Apotex opposed the release of Sanofi-Aventis from the undertaking as to damages given on 30 October 2008 in respect of the interlocutory injunction. As the undertaking relates to the interlocutory injunction (which will be discharged on the making of the final injunction in Sanofi-Aventis’s favour), the undertaking must be released. Apotex’s concern is that Sanofi-Aventis has not disavowed the possibility that it might argue that the effect of the release of the undertaking is to deprive Apotex of its benefit should Apotex succeed in its foreshadowed appeal. I am not aware of any authority suggesting that this might be the effect of the release of the undertaking (that is, that by releasing the undertaking it will be as if the undertaking had never been given). Nevertheless, Sanofi-Aventis did not disavow the potential argument that is of concern to Apotex. In these circumstances, and for abundant caution, the release of the undertaking should be qualified to make clear that the release operates with effect from the date of the release and not otherwise.THE PATENT INJUNCTION